ACQUISITION OF NPO PETROVAX PHARM BY THE INTERROS GROUP
Interros Group is acquiring a controlling stake in NPO Petrovax Pharm, a Russian pharmaceutical company. The parties signed the documents in Moscow today. Arkady Nekrasov and Natalia Puchkova, NPO Petrovax Pharm founders, will retain a stake in the company, and will continue to participate in business management. Financial terms of the deal are not disclosed.
Aleksey Bashkirov, Chief Investment Officer of the Interros Group: “Interros Group’s strategy is to invest in leading companies in socially significant industries with high growth rates. The NPO Petrovax Pharm acquisition will allow it to develop quality production of unique Russian pharmaceutical innovations on a large scale.”
Arkady Nekrasov, Chief Executive Officer of NPO Petrovax Pharm: “NPO Petrovax Pharm entry into the Interros Group opens up wide opportunities to further fundamental research, and to effectively develop and commercialize innovative immunobiologic medicines and vaccines in Russian healthcare system”.
Interros Group is one of the largest investment companies in Russia, founded by Vladimir Potanin in 1990. The company’s projects are focused mostly in metals and mining (Mining and Metallurgical Company Norilsk Nickel), media (ProfMedia holding, Cinema Park, a chain of movie theaters, United Company Afisha-Rambler-SUP), real estate and tourism (Profestate Group and the Alpine Ski Resort Rosa Khutor), logistics and infrastructure (Interport, a managing company), and education (Russian International Olympic University). The company is one of major investors in the Sochi Winter Olympic Games 2014. At the beginning of 2013 Interros assets amounted to some $15 bln.
NPO Petrovax Pharm is a Russian research and development company that manufactures innovative pharmaceutical medicines and vaccines. NPO Petrovax Pharm is one of the most technologically advanced, state of the art Russian companies, and a top ten largest pharmaceuticals manufacturer. It produces Grippol Plus, a flu vaccine, to meet the national immunization schedule; Polyoxidonum, an immunomodulator; and other original immunobiologic medicines. The company owns several production facilities in Moscow and the Moscow region (certified according to GMP EU and ISO 9001). The company employs more than 600 highly qualified personnel. In 2012 the company sales exceeded $100 mln.